Orgenesis Inc. SG&A Expenses

SG&A Expenses of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative


Highlights and Quick Summary

  • SG&A Expenses for the quarter ending September 29, 2021 was $6.08 Million (a 107.51% increase compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses decreased by -21.82%
  • Annual SG&A Expenses for 2020 was $18.6 Million (a 116.6% increase from previous year)
  • Annual SG&A Expenses for 2019 was $8.6 Million (a -47.27% decrease from previous year)
  • Annual SG&A Expenses for 2018 was $16.3 Million (a 0.0% decrease from previous year)
  • Twelve month SG&A Expenses ending September 29, 2021 was $19.7 Million (a 11.71% increase compared to previous quarter)
  • Twelve month trailing SG&A Expenses increased by 4.14% year-over-year
Trailing SG&A Expenses for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$19.7 Million $17.6 Million $18.3 Million $18.9 Million
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of Orgenesis Inc.

Most recent SG&A Expensesof ORGS including historical data for past 10 years.

Interactive Chart of SG&A Expenses of Orgenesis Inc.

Orgenesis Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $6.08 $2.93 $2.92
2020 $7.78 $4.02 $3.61 $3.52 $18.62
2019 $3.26 $2.41 $2.79 $2.99 $8.6
2018 $7.61 $4.01 $3.32 $3.34 $16.3
2017 $3.18 $2.43 $2.27 $2.27 $9.19
2016 $1.27 $1.28 $2.17 $2.17 $2.17 $6.24
2015 $4.04
2014 $3.03
2013 $4.01
2012 $2.67
2011 $2.68

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.